Promising Neoadjuvant Pepinemab Results in Head & Neck Cancer at ASCO
Vaccinex announced new data on pepinemab’s mechanism of action in enhancing immune responses to checkpoint therapies in neoadjuvant head...
BioXcel’s Pivotal Phase 3 Trial for Agitation in Bipolar or Schizophrenia Gets Positive DSMB Recommendation
BioXcel Therapeutics announced positive safety results from the first 115 patients in its SERENITY At-Home Phase 3 trial of...
SPUR Therapeutics Publishes Preclinical Data for Gaucher Disease Gene Therapy
Spur Therapeutics announced preclinical data for FLT201, its gene therapy candidate for Gaucher disease, published in Molecular Therapy. The...
Vaxart Doses 10,000 in Phase 2b COVID-19 Trial
Vaxart dosed the first patient in the 10,000-participant phase of its Phase 2b clinical trial for its oral COVID-19...
Fate Therapeutics Reveals Promising Data on Off-the-Shelf CAR T-Cell Therapy at EULAR 2025
Fate Therapeutics will present clinical and preclinical data from its off-the-shelf cell therapy platform at the European Congress of...
Oric-944 Shows Promising Efficacy and Safety in mCRPC Trial
ORIC Pharmaceuticals announced positive preliminary data from a Phase 1b trial of ORIC-944, a potential best-in-class PRC2 inhibitor, combined...
Taysha Gene Therapies Announces Pivotal Trial Design for TSHA-102 in Rett Syndrome
Taysha Gene Therapies announced positive clinical data from Part A of its REVEAL trials for TSHA-102 in Rett syndrome,...
Uncommon Breakthrough Data for Novel Peanut Allergy Treatment
Intrommune Therapeutics’ Oral Mucosal Immunotherapy (OMIT) platform, delivered via a specialized toothpaste containing peanut protein (INT301), has shown promising...
Vittoria Biotherapeutics Presents Trial-in-Progress Poster for VIPER-101 at ASCO 2025
Vittoria Biotherapeutics is presenting its Phase 1 clinical trial results for VIPER-101, a gene-edited CAR-T therapy targeting CD5-positive T-cell...
Scynexis Resumes Patient Dosing in Phase 3 MARIO Study
SCYNEXIS has restarted patient dosing in its Phase 3 MARIO study of oral ibrexafungerp for invasive candidiasis after resolving...